drugset / Trial / NCT05582278
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
RandomizedParallel-groupOpen-labelTreatment
Summary
Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect of D-TACE for patients in Advanced Unresectable HCC. The investigators previous study also revealed similar results in Advanced Unresectable HCC patients treated with D-TACE. Recently, the investigators previous study demonstrated that, compared with D-TACE, hepatic arterial infusion chemotherapy (HAIC) may improve tumor response in Advanced Unresectable HCC. Thus, the investigators carried out this prospective nonrandomized control to demonstrate the superiority of HAIC-based combination therapy over D-TACE-based combination therapy.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levoleucovorin | Unknown | 200 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Other |
| Subject | Pirarubicin | Small molecule | 60 mg | Other |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Other |
| Background | Lenvatinib | Small molecule | 8 mg | — |
| Background | Lenvatinib | Small molecule | 12 mg | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | — |